← Til baka á Heimildir
EEA-DATA-031 Sérfræðigreining Miðlungs
EES/ESB-löggjöf Efnahagslegt critical medicines alliance alvotech
The EU Critical Medicines Alliance was formally launched in late April 2024, with approximately 250 member organisations. Icelandic biopharmaceutical company Alvotech S.A. was listed as a participant. Iceland's broader participation in the Alliance was described as 'under consideration.' Icelandic Health Minister Ásta Valdimarsdóttir attended the informal EU health ministers' meeting in April 2024, where the Alliance was discussed. EEA/EFTA health ministers were specifically invited to participate in health sector discussions. This illustrates that EEA membership provides pathways for Icelandic companies and institutions to participate in EU strategic initiatives, though participation terms may differ from full EU membership.
Dagsetning 3. maí 2024
Síðast staðfest 23. mars 2026
Svið Efnahagslegt
Heimildaflokkur Sérfræðigreining

Heimild

Brussel-vaktin (Sendiráð Íslands í Brussel) — 3. maí 2024

Skoða heimild ↗

Fyrirvarar

Alvotech's participation may be as a company, not as a representative of Iceland. The 'under consideration' language regarding Iceland's broader participation suggests it is not automatic. The Critical Medicines Alliance is a stakeholder platform, not a binding framework — participation does not equate to policy influence. Terms of EEA/EFTA state participation may be more limited than EU member state participation.

Tengdar heimildir (2)

EEA-LEGAL-026 EES/ESB-löggjöf

In October 2024, an EFTA Task Force (established July 2024) published a report titled 'Cross-sectoral EU initiatives: The way ahead for the EEA', identifying four categories of EU legislation that structurally threaten EEA/EFTA market access: (1) rules with third-country trade provisions, (2) rules implementing EU industrial policy, (3) rules addressing security/defence, and (4) rules using EU cooperation programmes strategically. The task force warned that EEA/EFTA states risk being classified as third countries in EU market sectors, excluded from supply chain security measures, and subjected to anti-circumvention measures. This represents an institutional acknowledgement that the EEA framework faces structural erosion as EU legislation increasingly addresses extra-EEA matters.

 EEA-LEGAL-027 EES/ESB-löggjöf

In January 2025, Iceland, Norway, and Liechtenstein submitted a joint EEA/EFTA comment on the EU's Single Market Strategy, warning that 'EU legislation increasingly addresses extra-EES matters' and that 'new barriers risk market fragmentation.' The comment asserted EEA/EFTA states' equal rights to participate in EU programmes for 2028–2034 and cautioned against state aid rule modifications that could disadvantage EEA participants. This represents a formal institutional expression of concern that the EEA framework is being eroded by EU legislation expanding beyond its original scope.